Clay
2017-06-01 04:25:14 UTC
A few years back, scientists at the biotechnology company Amgen set
out to replicate 53 landmark studies that argued for new approaches to
treat cancers using both existing and new molecules. They were able to
replicate the findings of the original research only 11 percent of the
time.
In 2011, Bayer pharmaceuticals reported similar reproduction work. Of
the 67 projects they conducted to rerun experiments (47 of which
involved cancer), only about 25 percent ended with results in line
with the original findings.
https://nyti.ms/2scNFLl
out to replicate 53 landmark studies that argued for new approaches to
treat cancers using both existing and new molecules. They were able to
replicate the findings of the original research only 11 percent of the
time.
In 2011, Bayer pharmaceuticals reported similar reproduction work. Of
the 67 projects they conducted to rerun experiments (47 of which
involved cancer), only about 25 percent ended with results in line
with the original findings.
https://nyti.ms/2scNFLl